Investors / Belgium / Newton Biocapital
Newton Biocapital
Venture capital · Brussels, Belgium · Europe
Newton Biocapital is a life sciences investment fund with offices in Brussels and Tokyo. It invests in early-stage companies developing treatments and technologies for chronic health conditions, and supports them as an active board-level investor.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechchronic diseasemedical devicestherapeuticshealthcare
Your fit with Newton Biocapital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNewton Biocapital lists 13 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 38% of its companies are based in Japan. It invests most often alongside AdBio partners, Agoranov and Asabys Partners.
Counts come from funding rounds that name Newton Biocapital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Newton Biocapital's whole history. Rounds on record name 1 company; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 59th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| AdBio partners | 1 |
| Agoranov | 1 |
| Asabys Partners | 1 |
| Criteria Bio Ventures | 1 |
| DBJ Capital | 1 |
| Eisai Innovation Inc. | 1 |
| F-Prime Capital | 1 |
| Fund+ | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Newton Biocapital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Newton Biocapital| Date | Company | Stage |
|---|---|---|
| 24 Mar 2025 | Series A |
Round details for Newton Biocapital
Amounts, full round histories and every co-investor in Newton Biocapital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aboleris Pharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and organ transplantation rejection. | Healthcare & Biotech | Portfolio page | ||
| Acticor Biotech is a clinical stage biopharmaceutical company developing an innovative treatment for thrombotic diseases, with a primary focus on Acute Ischemic Stroke. | Healthcare & Biotech | Portfolio page | ||
| AdipoPharma is developing a unique first-in-class insulin sensitizer that targets the adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities. | Healthcare & Biotech | Portfolio page | ||
| Augustine Therapeutics develops novel HDAC6 inhibitors for the treatment of chronic diseases | Healthcare & Biotech | Mar 2025Series A | Funding round | |
| Deuteroncology is developing a deuterated MET kinase inhibitor as a potential targeted therapy for MET driven disease | Healthcare & Biotech | Portfolio page | ||
| The company develops new technologies for RNA targeting therapies and editing | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| J-Pharma develops innovative new drugs through SLC transporter creation, contributing to people's health and hope, particularly for unmet medical needs. | Healthcare & Biotech | Portfolio page | ||
| Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers | Healthcare & Biotech | Portfolio page | ||
| Prism Biolab develops new drugs using its PepMetics technology | Healthcare & Biotech | Portfolio page | ||
| Santero Therapeutics develops first-in-class medicines that target the root cause of treatment-refractory disease | Healthcare & Biotech | Portfolio page | ||
| Synergia Medical develops an investigational neuromodulation platform using optoelectronic technology | Healthcare & Biotech | Portfolio page | ||
| Tensegrity Pharma eliminates R&D bottlenecks for novel value for patients. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- newtonbiocapital.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 24 Mar 2025
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Newton Biocapital's profile as data
Pull Newton Biocapital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/newtonbiocapital.com
# also
GET /v1/firms/newtonbiocapital.com/portfolio
GET /v1/firms/newtonbiocapital.com/coinvestors
GET /v1/firms/newtonbiocapital.com/news